China peptide therapeutics market is anticipated to project a CAGR of 6.8%, during the forecast period. China has a considerable manufacturing capability in the pharmaceutical industry which aids in supporting its overall economic development. The increasing number of drug approvals are also expected to provide expansion opportunities for the peptide therapeutics market. For instance, in 2019, the National Medical Products Administration (NMPA) has approved a total of 51 new drugs including one synthetic peptide analog for Hansoh Pharma. Additionally, numerous global companies are also expanding their R&D centers across the country which will also aid the growing shares of the peptide therapeutics market.

Visit for Global Peptide Therapeutics Market Report at: https://www.omrglobal.com/industry-reports/peptide-therapeutics-market

China peptide therapeutics market is segmented on the basis of route of administration and application. Based on the route of administration, the market is bifurcated into parenteral administration and oral administration. On the basis of application, the market is segmented into cancer, metabolic disorder (diabetes & obesity), gastrointestinal disorders, central nervous system disorders, respiratory disorders, and others including chronic kidney diseases, osteoporosis, and autoimmune disorder. Among these applications, metabolic disorder dominates the market in China. 

Furthermore, some of the global and local players in the market include Eli Lilly & Co., Amgen Inc., AstraZeneca Plc, Astellas Inc., Pfizer Inc., and Teva Pharmaceuticals Co. Ltd. These companies are using several strategies to expand market share and gain a competitive advantage over their competitors. The strategies include new product launches, mergers and acquisitions, partnerships, and collaborations. 

For instance, in November 2019, AstraZeneca Plc announced the opening of new R&D centers focused on drug development and artificial intelligence (AI) in Shanghai, China. In addition to this, the company will also partner with China International Capital Corporation Ltd. (CICC) to launch a potentially $1 billion fund whose investments will aim to advance innovation in China’s healthcare system.

Research Methodology

The market study of the China peptide therapeutics market is incorporated by extensive primary and secondary research conducted by the research team at OMR. Secondary research has been conducted to refine the available data to breakdown the market into various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings authenticity to our reports.

Secondary Sources Include:

• Financial reports of companies involved in the market.
• Authentic public databases 
• Whitepapers, research-papers, and news blogs.
• Company websites and their product catalog.

The report is intended for drug manufacturing companies, pharmaceutical companies, insulin manufacturers, diabetes management companies, government organizations, regulatory bodies, hospitals & pharmacies, research institutes, and other market participants for overall market analysis and competitive analysis. The report provides an in-depth analysis of market size, intended quality of the service preferred by consumers. The report will serve as a source for 360-degree analysis of the market thoroughly integrating different models. 

Market Segmentation:

1. China Peptide Therapeutics Market Research and Analysis by Route of Administration
2. China Peptide Therapeutics Market Research and Analysis by Application

The Report Covers:

• Comprehensive research methodology of the China peptide therapeutics market.
• This report also includes a detailed and extensive market overview with key analyst insights.
• Exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
• Analysis of regional regulations and other government policies impacting the China peptide therapeutics market.
• Insights about market determinants which are stimulating the China peptide therapeutics market.
• Detailed and extensive market segments with regional distribution of forecasted revenues.
• Extensive profiles and recent developments of market players.